Gilead Sciences (NASDAQ:GILD) Updates FY 2026 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of -0.650–0.300 for the period, compared to the consensus estimate of -0.790. The company issued revenue guidance of $30.1 billion-$30.4 billion, compared to the consensus revenue estimate of $30.5 billion.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on GILD shares. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Barclays reduced their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. Finally, Wall Street Zen cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $157.93.

Gilead Sciences Stock Up 3.1%

Shares of GILD stock traded up $4.10 on Tuesday, hitting $135.25. 10,084,002 shares of the stock were exchanged, compared to its average volume of 7,149,559. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $167.92 billion, a P/E ratio of 18.43 and a beta of 0.32. Gilead Sciences has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The business has a 50-day moving average of $129.55 and a 200 day moving average of $136.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.26) by $0.51. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences has set its FY 2026 guidance at -0.650–0.300 EPS. Equities analysts anticipate that Gilead Sciences will post -0.78 EPS for the current year.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 67,000 shares of company stock worth $8,687,140 over the last ninety days. Insiders own 0.30% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Second-quarter product sales increased 8% year over year and exceeded Wall Street expectations, driven by double-digit growth in Gilead’s HIV portfolio. Gilead second-quarter sales rise 8%, beating Wall Street estimates
• Positive Sentiment: Gilead reported quarterly EPS of negative $6.75, which was better than the consensus estimate of negative $7.26. The result included substantial acquisition-related R&D costs, while the company reported a 48.19% return on equity and a 30.99% net margin. Gilead quarterly earnings release
• Positive Sentiment: Fiscal 2026 EPS guidance of negative $0.65 to negative $0.30 is better than the consensus estimate of negative $0.79, suggesting earnings expectations may be more resilient than the headline quarterly loss indicates.
• Positive Sentiment: California’s highest court ruled in Gilead’s favor in a case arguing that drugmakers have a duty to develop potentially safer medicines. The decision could reduce legal exposure related to that claim. California court rules for Gilead
• Neutral Sentiment: Investors are evaluating Yeztugo as a possible future HIV growth engine, though the available report does not provide specific sales or clinical updates.
• Negative Sentiment: Gilead lowered its full-year Veklury forecast after second-quarter sales of the COVID-19 treatment fell 81%, highlighting continued pressure from the fading pandemic market. Gilead swings to loss as HIV sales lift revenue
• Negative Sentiment: Fiscal 2026 revenue guidance of $30.1 billion to $30.4 billion is below the $30.5 billion analyst consensus, and acquisition-related R&D expenses pushed the company to a quarterly loss.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Venture Visionary Partners LLC increased its holdings in Gilead Sciences by 1.2% in the fourth quarter. Venture Visionary Partners LLC now owns 6,422 shares of the biopharmaceutical company’s stock worth $788,000 after buying an additional 76 shares during the last quarter. Binnacle Investments Inc lifted its stake in Gilead Sciences by 11.8% in the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 83 shares during the last quarter. Vermillion & White Wealth Management Group LLC lifted its stake in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Wealthspire Retirement LLC grew its position in Gilead Sciences by 0.6% in the fourth quarter. Wealthspire Retirement LLC now owns 15,866 shares of the biopharmaceutical company’s stock worth $1,947,000 after acquiring an additional 93 shares in the last quarter. Finally, Rossby Financial LCC increased its stake in shares of Gilead Sciences by 12.2% during the 4th quarter. Rossby Financial LCC now owns 926 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 101 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.